Evidence map›Paper›PMID 41125368›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Mogamulizumab Concentration-guided Allogeneic Transplantation and Successful Intrathecal Chemotherapy for Central Nervous System-relapsed Adult T-cell Leukemia/Lymphoma.

Saki Fujii, Kazuki Sakatoku, Yosuke Nakaya, Mirei Horiuchi, Kentaro Ido, Yosuke Makuuchi, Masatomo Kuno, Hiroshi Okamura, Mitsutaka Nishimoto, Yasuhiro Nakashima and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Saki FujiiDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Kazuki SakatokuDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Yosuke NakayaDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Mirei HoriuchiDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Kentaro IdoDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Yosuke MakuuchiDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Masatomo KunoDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Hiroshi OkamuraDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Mitsutaka NishimotoDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Yasuhiro NakashimaDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Mika NakamaeDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Masayuki HinoDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University, Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult T-cell leukemia/lymphoma (ATL) has a poor prognosis, with mogamulizumab effectively controlling the disease but increasing graft-versus-host disease (GVHD) risk during transplantation if residual levels persist. We herein report a 61-year-old patient with acute-type ATL who underwent mogamulizumab concentration-guided transplantation to avoid severe GVHD despite human leukocyte antigen-mismatched donor transplantation. Post-transplant central nervous system (CNS) relapse was successfully managed with intrathecal chemotherapy alone, achieving long-term remission. Two years post-transplantation, the patient remains in complete remission without relapse or chronic GVHD. This case highlights the importance of assessing mogamulizumab levels for optimal transplantation timing and intrathecal chemotherapy as a strategy for CNS-limited ATL relapse.

Indexed as

Antibodies, Monoclonal, HumanizedCentral Nervous System NeoplasmsHematopoietic Stem Cell TransplantationLeukemia-Lymphoma, Adult T-CellAntineoplastic Combined Chemotherapy ProtocolsGraft vs Host DiseaseHumansInjections, SpinalMaleMiddle AgedRecurrenceTransplantation, HomologousTreatment OutcomeAntibodies, Monoclonal, Humanizedmogamulizumabadult T-cell leukemiacentral nervous systemintrathecal chemotherapymogamulizumabrelapse

Identifiers

PMID41125368
PMCPMC13265091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.